Detalhe da pesquisa
1.
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing.
Cell
; 172(1-2): 205-217.e12, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29307488
2.
Pathogenic Germline Variants in 10,389 Adult Cancers.
Cell
; 173(2): 355-370.e14, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29625052
3.
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
Nat Immunol
; 20(7): 835-851, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31160797
4.
Breast tumours maintain a reservoir of subclonal diversity during expansion.
Nature
; 592(7853): 302-308, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762732
5.
Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Annu Rev Med
; 75: 31-48, 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758237
6.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652354
7.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
8.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710187
9.
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Mol Cancer
; 23(1): 64, 2024 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38532456
10.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer
; 130(3): 400-409, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864520
11.
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
J Hepatol
; 80(2): 322-334, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972659
12.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297981
13.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914339
14.
Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
Ann Surg Oncol
; 31(2): 974-980, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973647
15.
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Ann Surg Oncol
; 31(4): 2244-2252, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38161200
16.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
17.
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
Cancer
; 129(17): 2685-2693, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129197
18.
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Cancer
; 129(14): 2201-2213, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016732
19.
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.
Oncologist
; 28(4): 368-372, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200910
20.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med
; 383(13): 1207-1217, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32955176